Antibodies to human papillomavirus type 16 E7 related to clinicopathological data in patients with cervical carcinoma

23Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

Abstract

Aims: To investigate the correlation between antibodies to the transforming protein E7 of human papillomavirus (HPV) type 16 and clinicopathological indices in women with cervical squamous carcinoma. Methods: A synthetic peptide of the HPV type 16 E7 protein (amino acids 6 to 35) was used to screen sera from 29 children, 130 women with cervical intraepithelial neoplasia, 443 women with cervical cancer, and 222 controls, for antibodies against this viral antigen. Bivariate and multivariate analyses were used to investigate the correlation between the serological status in the pretreatment sera and clinicopathological indices (size of the lesion, histological grade, stromal infiltration, vascular invasion, and nodal spread). Survival analysis was done using the Cox regression model for all FIGO stages and stages IB and IIA. Results: Cervical carcinoma patients had a significantly higher prevalence of antibodies to synthetic peptide E7/6-35 than women with cervical intraepitheial neoplasia (17.7% v 7%, p<0.005) or controls (17.7% v 11%, p<0.05). Bivariate analysis of the data on the presence of anti-E7/6-35 antibodies in the pretreatment sera from these patients and clinicopathological indices showed a significant correlation between the presence of anti-E7/6-35 antibodies and the size of the lesion (p=0.0009), histological grade (p= 0.031), and lymph node metastasis (p= 0.011). In addition, the Cox regression model, analysing four risk factors which can be determined before treatment, showed a significant correlation between the presence of anti-E7/6-35 antibodies and a worse prognosis (p=0.003). Survival analysis revealed that both for all FIGO stages (p=0.0005) and for stages IB and IIA alone (p=0.0021), anti-E7/6-35 positive patients before treatment had a significantly shorter life expectancy. Conclusions: The presence of antibodies E7/6-35 in pretreatment sera from patients with cervical carcinoma correlates with the size of the lesion, lymph node involvement, and a worse prognosis.

Cite

CITATION STYLE

APA

Baay, M. F. D., Duk, J. M., Burger, M. P. M., Walboomers, J., Ter Schegget, J., Groenier, K. H., … Herbrink, P. (1995). Antibodies to human papillomavirus type 16 E7 related to clinicopathological data in patients with cervical carcinoma. Journal of Clinical Pathology, 48(5), 410–414. https://doi.org/10.1136/jcp.48.5.410

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free